Frank Bonner

Head of Non-Clinical Safety at Inflection Biosciences

Frank has over 35 years of experience of toxicology and non-clinical drug development, gained in pharmaceutical (Senior Vice President, Sanofi), and contract research industries, and including 15 years as an independent consultant supporting the development of a diverse range of molecules. He has a comprehensive knowledge of non-clinical safety assessment including all aspects of regulatory guidance and advocacy, outsourced programme management, mechanistic toxicology and the application of new technologies to improve predictive screening.

He is a fellow of the British Toxicology Society, Past President of the Society and Visiting Professor in the Division of Integrative Systems Medicines at Imperial College, London. He has served as a Scientific Advisor for a number of technology and drug development SME’s and has Board level experience gained through various appointments including Executive Director, Stem Cells for Safer Medicines; Non-Executive Chairman, Maccine Pte, Singapore; Executive Director, Life Science Research Inc. etc.


Org chart

This person is not in the org chart


Teams


Offices

This person is not in any offices


Inflection Biosciences

Inflection Biosciences Ltd is an early stage, drug development company with a focus on discovering and developing innovative small molecule therapeutics addressing major unmet needs in cancer.


Industries

Headquarters

Blackrock, Ireland

Employees

1-10

Links